There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb, Merck, AstraZeneca and Roche are speeding ahead with their research in the field, with Sanofi, Novartis and Pfizer racing to catch up.
The promises are coming home to roost for AstraZeneca CEO Pascal Soriot. Or so reports The Sunday Times, which says the U.K.-based company is once again under pressure to put Soriot's bonus pay on the line for the big goals he touted in defending against Pfizer's $100 billion takeover bid last year.
Pushing through on a plan to get out of the early-stage anti-infectives R&D space, AstraZeneca is spinning out its Waltham, MA-based company into an independent biotech, a move that will have an impact on the 95 staffers remaining in the swiftly dwindling operation.
Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.
Actavis won the FDA's blessing for a new combination antibiotic treatment targeting drug-resistant infections, setting the stage for a showdown with Merck and its $9.5 billion splash into the field.
AstraZeneca is out to get some more shots on goal in immunology, pairing up with a nascent biotech in hopes of developing oral medicines for psoriasis, arthritis and other diseases.
AstraZeneca has struck a deal with BioData to use Labguru across its preclinical R&D sites. The deal will see AstraZeneca phase out its current patchwork of legacy systems in favor of BioData's web-based lab management system.
Just who is the neuroscientist and university professor AstraZeneca has nominated to its board of directors? A sometime critic of the pharma industry, the Financial Times points out.
AstraZeneca's respiratory aspirations just took a hit. While it guns for a lead in the field, it may have to do so without much help from asthma med Pulmicort, which lost a patent in U.S. federal court Friday.
Looking to tie its two big R&D hubs in Cambridge, U.K., and Gothenburg, Sweden, closer together, AstraZeneca has struck a deal to reserve 20 seats on a Sun Air flight that will make a round-trip journey each day from Monday through Thursday.